Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group.
|
| Abstract |
Peripheral T-cell lymphoma (PTCL) is generally characterized by poor prognosis after conventional chemotherapy compared with aggressive B-cell lymphoma. To elucidate the role of high-dose chemotherapy (HDCT) with auto-SCT, we retrospectively analyzed the outcomes of 39 patients with PTCL who received HDCT and auto-SCT between 1990 and 2005. Eleven patients were histologically typed as angioimmunoblastic, nine as anaplastic large-cell lymphoma, seven as natural killer/T-cell lymphoma and twelve as PTCL unspecified. Clinical conditions at transplantation were complete response (CR) in 27 patients and non-CR in 12 patients. Thirty-two patients received a pre-transplant conditioning regimen (MCEC) comprising ranimustine, carboplatin, etoposide and CY, and seven did other TBI-based regimens. Rapid engraftment was obtained in all cases, and transplant-related death was not seen. An estimated 5-year OS was 62.1% with a median follow-up of 78 months. The 5-year OS was significantly higher in patients transplanted during complete response than in those during other disease status (71.4% vs 27.3%, P=0.046). HDCT supported by auto-SCT may therefore be effective as consolidation in CR for PTCL treatment.
|
|---|---|
| Authors | A Numata, T Miyamoto, Y Ohno, T Kamimura, K Kamezaki, T Tanimoto, K Takase, H Henzan, K Kato, K Takenaka, T Fukuda, N Harada, K Nagafuji, T Teshima, K Akashi, M Harada, T Eto, Fukuoka Blood and Marrow Transplantation Group |
| Journal | Bone marrow transplantation (Bone Marrow Transplant) Vol. 45 Issue 2 Pg. 311-6 (Feb 2010) ISSN: 1476-5365 [Electronic] England |
| PMID | 19597416 (Publication Type: Journal Article) |
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!